RT Journal Article
SR Electronic
T1 Blood neurofilament light concentration at admittance: a potential prognostic marker in COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.07.20189415
DO 10.1101/2020.09.07.20189415
A1 Aamodt, Anne Hege
A1 Høgestøl, Einar August
A1 Popperud, Trine Haug
A1 Holter, Jan Cato
A1 Dyrhol-Riise, Anne Ma
A1 Tonby, Kristian
A1 Stiksrud, Birgitte
A1 Quist-Paulsen, Else
A1 Berge, Tone
A1 Barratt-Due, Andreas
A1 Aukrust, Pål
A1 Heggelund, Lars
A1 Blennow, Kaj
A1 Zetterberg, Henrik
A1 Harbo, Hanne Flinstad
YR 2020
UL http://medrxiv.org/content/early/2020/09/09/2020.09.07.20189415.abstract
AB Objective To test the hypotheses that blood concentrations of neurofilament light chain protein (NfL) and glial fibrillary acidic protein (GFAp) can serve as biomarkers for disease severity in COVID-19 patients.Methods Forty-seven inpatients with confirmed COVID-19 had blood samples drawn on admission for assessing serum biomarkers of CNS injury by Single molecule array (Simoa). Concentrations of NfL and GFAp were analyzed in relation to symptoms, clinical signs, inflammatory biomarkers and clinical outcomes. We used multivariate linear models to test for differences in biomarker concentrations in the subgroups, accounting for confounding effects.Results In total, 21 % (n = 10) of the patients were admitted to an intensive care unit, whereas the overall mortality rate was 13 % (n = 6). Non-survivors had higher serum concentrations of NfL than patients who were discharged alive both in adjusted analyses (p = 2.6 × 10−7) and unadjusted analyses (p = 0.001). Serum concentrations of GFAp were significantly higher in non-survivors than survivors in adjusted analyses (p = 0.02). The NfL concentrations in non-survivors increased over repeated measurements, whereas the concentrations in survivors were stable. Significantly higher concentrations of NfL were found in patients reporting fatigue, while reduced concentrations were found in patients experiencing cough, myalgia and joint pain.Conclusion Increased concentrations of NfL and GFAp in COVID-19 patients on admission may indicate increased mortality risk. Measurement of blood biomarkers for nervous system injury can be useful to detect and monitor CNS injury in COVID-19.Competing Interest StatementA.H. Aamodt has received travel support, honoraria for advice or lecturing from Bayer, Boehringer Ingelheim, BMS, Allergan, Teva, Sanofi-Genzyme, Novartis, Roche, and Teva and research grant from Medtronic and Boehringer Ingelheim. T.H. Popperud has received honoraria for lecturing from Alexion and unrestricted research support from Octapharma. E. A. Høgestøl has received honoraria for lecturing from Biogen, Merck and Sanofi-Genzyme, and unrestricted research support from Merck and Sanofi-Genzyme. H.F. Harbo has received travel support, honoraria for advice or lecturing from Biogen Idec, Sanofi-Genzyme, Merck, Novartis, Roche, and Teva and an unrestricted research grant from Novartis. Kaj Blennow has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. H. Zetterberg has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).Funding StatementSupported by Oslo University Hospital, Research Council of Norway grant no 312780, Vivaldi Invest A/S owned by Jon Stephenson von Tetzchner.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Informed consents were obtained from all patients or next-of-kin if patients were incapacitated of giving consent. The study was approved by the South-Eastern Norway Regional Health Authority (reference number: 106624).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author, AHA. The data are not publicly available due to ethical restrictions.CNScentral nervous system;SARS-CoV-2severe acute respiratory syndrome coronavirus 2;ACE-2angiotensin-converting enzyme 2;NfLneurofilament light protein;GFApglial fibrillary acidic protein